Pomalidomide-PEG6-CO2H

Background Introduction

Pomalidomide-PEG6-CO2H is a specialized bifunctional molecule designed for targeted protein degradation applications. This conjugate consists of pomalidomide, a well-characterized cereblon (CRBN) E3 ligase ligand, linked to a carboxylic acid-terminated hexamethylene glycol (PEG6) spacer. The extended PEG6 linker enhances solubility and spatial flexibility, enabling efficient coupling of target-binding ligands for the construction of PROTACs (Proteolysis Targeting Chimeras).

Mechanism

The mechanism of action for Pomalidomide-PEG6-CO2H revolves around harnessing the ubiquitin-proteasome system for targeted protein degradation. Pomalidomide binds selectively to the cereblon E3 ubiquitin ligase within the cell. The PEG6 linker provides an optimal distance and flexibility for the attachment of various protein-targeting ligands via its terminal carboxylic acid group. In PROTAC design, once conjugated to a ligand for a protein of interest (POI), Pomalidomide-PEG6-CO2H simultaneously recruits both the CRBN E3 ligase and the POI, inducing their proximity. This ternary complex formation triggers ubiquitination of the POI by the ligase, marking it for degradation by the cellular proteasome.

Applications

Pomalidomide-PEG6-CO2H is widely utilized in the development of CRBN-based PROTACs and related bifunctional molecules for targeted protein degradation studies. Its applications include: (1) constructing customized PROTACs by linking to various protein-specific ligands through the PEG6-carboxyl group; (2) facilitating the study of structure-activity relationships and linker optimization in PROTAC research; (3) advancing drug discovery pipelines by enabling selective removal of disease-relevant proteins in oncology, neurodegenerative diseases, and immunological disorders. The PEG6 linker imparts improved pharmacokinetics and cell permeability, making it an ideal component for chemical biology, medicinal chemistry, and preclinical therapeutic research.

• PEG6 linker increases solubility and improves pharmacokinetic properties of PROTAC molecules.
• Carboxylic acid (CO2H) terminal enables versatile conjugation with target warheads for efficient CRBN E3 ligase recruitment.

Pomalidomide-PEG6-CO2H is a versatile E3 Ligase Ligand-Linker Conjugate designed for use in PROTACs, facilitating targeted protein degradation by linking E3 ligases to specific protein targets. The following provides a detailed description of this molecule, focusing on its linker, ligand, and the selection of target protein ligands.

Linker: The linker in Pomalidomide-PEG6-CO2H is a polyethylene glycol chain with six ethylene glycol units, providing moderate flexibility and ideal length for efficient spatial orientation. Its non-cleavable nature ensures stability in cellular environments, enhancing the conjugate's efficacy.

Ligand: The ligand component of this molecule is Pomalidomide, a well-characterized thalidomide derivative known for its high affinity to the cereblon E3 ubiquitin ligase. Its structural features facilitate effective recruitment of the E3 ligase, promoting targeted protein degradation.

Reactive Site: The reactive site of Pomalidomide-PEG6-CO2H is the carboxylic acid group, which couples efficiently with amine-containing target protein ligands. Recommended reaction types include amide bond formation, enabling stable and robust conjugation with minimal side reactions.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is an amine-functionalized small molecule or peptide, which can form a stable amide linkage with the carboxylic acid group. This compatibility ensures efficient and selective degradation of target proteins, making it suitable for studies aimed at elucidating protein function and validating therapeutic targets.